Results presented on Tuesday at the American Association for Cancer Reserch include data on the combined use of tissue and ...

The team is exploring whether biomarker testing could also identify patients who benefit more from immune checkpoint inhibitors after radiation.

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the results of a study ...

A study conducted by researchers from the Agency for Science, Technology and Research (A*STAR), National Cancer Centre Singapore (NCCS) and National University of Singapore (NUS), in collaboration ...

A new, error-corrected method for detecting cancer from blood ... of the Englander Institute for Precision Medicine and associate professor of medicine and of cell and developmental biology ...

Detection requires precision because most RNA circulating in the bloodstream originates from blood-forming cells rather than tumors. Rare tumor-derived RNA molecules are often masked by the ...

Perlman Department of Dermatology at NYU Grossman School of Medicine ... “The discovery of cell-free, circulating tumor DNA (ctDNA) as a direct, albeit imperfect, measurement of tumor ...

It can also detect cancer risk. This technology identifies changes in the immune system. It aids in precision ... amounts of circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs ...